The expanding role of anti-EGFR therapeutic modalities in colorectal cancer along with the growing number of cases potentially requiring such a treatment approach made the need for a correct and reliable identification of responding tumors even more relevant [1-7]. The gene discussed is EGFR; the disease is colorectal cancer.